Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma

Frontiers in Oncology

Oncology

Shuqi Xie¹  Fanming Kong¹  Yan Ou¹  Mengchao Wang¹  Dong Wang¹  Dan Yi¹  Chuanxiu Zeng¹  Liwei Chen¹  Lu Zhao¹ 

[1] Department of Oncology, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China;

关键词: targeted therapy;    immunotherapy;    research progress;    hepatocellular carcinoma;    combination therapy;   

DOI  :  10.3389/fonc.2023.1197698

 received in 2023-03-31, accepted in 2023-05-16,  发布年份 2023

来源: Frontiers

【 摘 要 】

Hepatocellular carcinoma is a common gastrointestinal malignancy with a high mortality rate and limited treatment options. Molecularly targeted drugs combined with immune checkpoint inhibitors have shown unique advantages over single-agent applications, significantly prolonging patient survival. This paper reviews the research progress of molecular-targeted drugs combined with immune checkpoint inhibitors in the treatment of hepatocellular carcinoma and discusses the effectiveness and safety of the combination of the two drugs to provide a reference for the further application of molecular-targeted drugs combined with immune checkpoint inhibitors in clinical practice.

【 授权许可】

Unknown   
Copyright © 2023 Xie, Wang, Zeng, Ou, Zhao, Wang, Chen, Kong and Yi